

21st BHIVA

Brighton


21-24th April 2015

Dr Christopher Wood

North Middlesex University Hospital




Mortality by cause of death and sex: E&W, 1997-2012



*Significant difference between men and women ($p < 0.05$)



Mortality among women by cause of death: E&W, 1997-2012




1. Pneumocystis (PCP)
2. Lymphoma
3. Tuberculosis


- Median age of death 39 IQR [33-46]
- 90% diagnosed late
- Median survival of 55 days [9-374]

- Median age of death 41 [34-49]
- 72% diagnosed late
- Median survival of 424 days [23-1,652]

Deaths among adults diagnosed with HIV in the era of ART: England and Wales, 1997-2012



Classification of deaths among HIV patients



Death Audit

- 2012 - London-wide death audit started
- 2013 – London - North Central Sector Network – Quarterly Morbidity and Mortality Meetings set up
- Mortimer Market/UCLH + Royal Free + North Middlesex Hospitals
- Approx 10,000 Adult patients
- Format of meetings – Present overall mortality data by unit
- Discuss selected individual cases in more detail
- Meetings are now minuted

Aims of the Mortality Meetings

- To optimise clinical care and improve patient outcomes
- Share experience and clinical practice
- Peer review
- Clinical governance
- Education
- Identify clinical issues – eg access to specialised procedures such as brain biopsies
- Develop shared protocols and local guidelines where appropriate
- Opportunity to share the lessons learned from post mortems more widely

Value of post mortems

- Patients presenting with AIDS often have wide differential diagnoses and multiple pathologies
- Aim is to improve patient outcomes and survival
- AIDS Medicine still a relatively young specialty
- Changing patterns of pathology
- Understanding has often driven by individual cases/case series
- Post mortems offer an opportunity to learn and maybe prevent further deaths and morbidity
- Can sometimes help families (and clinical staff) come to terms with a patient's death

Summary of deaths -2013 -2014

- 64 cases presented
- 53 males/ 11 females
- Average age 54 yrs (21 – 81)

- Antiretrovirals
 - Yes – 43 patients
 - No - 6 patients
 - Poorly adherent – 9 patients

CD4 & HIV Viral loads at Time of death (TOD)

CD4 counts nearest TOD

- > 500 = 19 patients
- 350-500 = 16
- 200-350 = 7
- < 200 = 19

HIV Viral Load TOD

- < 40 copies/ml = 40 patient
- 40 – 1000 = 5
- 1000 – 10,000 = 4
- 10,000 – 100,000 = 3
- > 100,000 = 4

Years post HIV Diagnosis

- < 1 year = 4 patients
- 1-5 years = 8
- 5-10 years = 22
- 10-20 years = 18
- > 20 years = 8

Causes of death

• Non-AIDS-related cancer:	12	• CVD:	4
• Sepsis & pneumonia:	11	• CNS	4
• AIDS- related cancer:	9	• AIDS OIs:	3
• Liver disease:	7	• GI:	2
• Not known/found at home:	6	• MTB:	2
		• Respiratory:	2
		• Suicide:	1
		• Malaria:	1

Gender	Age	CD4	CD4 nadir	ARVs	V/Load	Year of HIV diagnosis	Ethnicity	Post mortem	Cause of death
Female	51	970	210	YES	< 20	1998	Black African	No	Pneumonia, Coma, CVA, BP
Male	55	640	80	YES	< 20	2000	White British	No	Cerebral mets, ?Primary Ca
Male	43	70	10	YES	< 20	2008	White - Europe	No	Liver failure, HCV/HBV + alcohol
Male	71	370	40	YES	< 20	1995	Middle-eastern	No	Oesophageal Ca + Widespread mets
Male	60	340	120	YES	< 20	2009	Black African	Yes – no change	Recurrent VTE + Sepsis
Male	67	140	50	YES	< 20	2002	Black Carib.	No	T – Cell Lymphoma
Male	68	410	?	NO	368,000	2008	White British	No	Alcoholic liver disease
Male	55	30	20	YES	< 20	2014	White - Europe	Yes – gave the diagnosis	‘Intravascular’ Non-Hodgkins Lymphoma
Male	67	490	40	YES	< 20	2006	White British	No	Lung fibrosis + bronchiectasis

Brief notes on the 9 cases

- 8/9 cases on suppressive therapy
- 2 Liver disease
- 2 Lymphomas (1 only diagnosed post-mortem)
- 2 Non-HIV related cancers
- 1 Catastrophic CVA
- 1 case of Idiopathic pulmonary fibrosis + aggressive bronchiectasis
- 1 Complex multi-system disorder (recurrent thromboembolic disease + sepsis)

The Pre-Mortem Virtual Post Mortem

- A useful thought experiment
- Confronted with a gravely ill deteriorating patient
- Try to imagine the Morbidity and Mortality Meeting and Post Mortem results –which tissue sample will give the result- can we access it?
- Wednesday's Case History of a case of disseminated Histoplasmosis – ITU team discussing the post mortem with the HIV team while patient in extremis but alive – patient now alive and recovered
- Compile experience of unusual cases from M&Ms and PMs
- For example, HHV8-related diseases, Lymphoma, CD8 encephalitis, Histoplasmosis and also common diseases presenting uncommonly

EQUALITY AND THE LAW

The *Equality Act 2010* states that all individuals living with HIV are protected from discrimination. People living with HIV are protected under disability discrimination as HIV is always defined as a disability under law. Protection against disability discrimination also includes discrimination in service provision. For example, a person cannot be denied a service on the basis of their disability. It also protects a person from being denied a service or being treated less favourably because they are linked or associated with a disabled person. To deny families the right for an autopsy to be carried out on their loved one purely because he/she has lived with HIV risks claims of discrimination and is unlawful under current legislation. It cannot be argued that discrimination is necessary because of the risk of HIV transmission, as current evidence proves HIV does not pose a high risk to practitioners.

Published in 'The Biomedical Scientist', June 2013. Zoe Rutherford is a senior anatomical pathology technologist at St Thomas' Hospital, London.

“It is for that reason that as part of the 2014/15 planning guidance we enhanced our expectations around the systems and processes Trusts should have in place for mortality surveillance and monitoring, including;

- having an early warning system in place for deteriorating patients
- screening all deaths for evidence of sub-optimal care
- thorough reviews of any deaths with evidence of sub-optimal care
- a Trust wide mortality review group for a multi-disciplinary team to identify and consider themes of the reviews”

Circular from: **Mortality Assurance**
Stan Silverman, Deputy Medical Director, NHS TDA



CROI 2010 Paper # 398

Fatal CD8⁺ T Cell Encephalitis: An Observational Autopsy Study of an Emerging Complication in HIV-1-infected African Patients on Effective Long-term ART

Sebastian Lucas^{*1}, KT Wong², and U Mahadeva³

¹King's Coll London Sch of Med, UK; ²Univ of Malaysia, Kuala Lumpur; and ³Guy's and St Thomas' Hosp, London, UK

Background: Combination ART (cART) has reduced disease complications in the brain of patients with HIV, such as HIV encephalitis, toxoplasmosis, and Jacob Creutzfeldt (JC) virus encephalitis. It has introduced new brain syndromes, some fatal, such as the immune reconstitution inflammatory syndrome (IRIS) to HIV, JC virus, and *Cryptococcus*. We have identified a new group of patients on apparently successful cART, who unexpectedly deteriorated and died with characteristic brain pathology.

Methods: Review of autopsies performed in a London hospital, with pre-mortem clinical, imaging and laboratory data, and brain biopsy of 1 non-autopsied deceased patient. Inclusion criteria were: on cART >4 years, clinically stable, CD4 count >200, HIV viral load undetectable or <250, acute neurological deterioration with brain swelling, death within 1 to 4 weeks of onset, brain histopathology showed white matter CD8⁺ T cell encephalitis.

Results: From 2002 to 2010, we identified 6 patients: 4 female : 2 male, median age 43 years, all African. Pre-mortem they had diffuse cerebral edema, raised intracranial pressure, and white matter hyper-intensity on MRI scan, without focal lesions. Histologically, the whole neuraxis white matter showed perivascular and parenchymal CD8⁺ T cell infiltration (CD38⁺) and microgliosis. CD4⁺ T cells, CD20⁺ B cells, and neuronophagia were scant; HIVp24 antigen, natural killer (NK) cells, demyelination and identifiable infectious agents were absent. Pre-mortem cerebrospinal fluid (CSF) and post-mortem brain tissue PCR analysis, in 2 cases, showed no viruses on standard encephalitis screen. T cell clonality analysis (β and γ gene) on paraffin to embedded brain tissue (n = 4) found no dominant clone. The extra-cranial tissues did not show infiltration by CD8⁺ T cells. Blood CD8 counts at time of death were median 1065 (range 306 to 2001) with no consistent historical trend. All patients were on different cART regimes; 2 additional African patients, on similar long-term cART who had recently stopped treatment and had rising viral loads and falling CD4 counts, suffered a similar clinical syndrome and had identical pathology.

Conclusions: The pathogenesis of this acute brain pathology is not typical IRIS, HIV encephalitis, T cell lymphoma, incidental viral encephalitis, diffuse infiltrative lymphocytosis syndrome, or known drug toxicity. It is an immune activation/dysregulation syndrome of uncertain trigger, probably with an associated abnormal blood to brain barrier. African ethnicity suggests a genetic factor.

CASE REPORT

Aurélie Vendrely · Boris Bienvenu · Jacques Gasnault
Jean Baptiste Thiebault · Dominique Salmon
Françoise Gray

Fulminant inflammatory leukoencephalopathy associated with HAART-induced immune restoration in AIDS-related progressive multifocal leukoencephalopathy

Received: 10 November 2004 / Revised: 22 December 2004 / Accepted: 22 December 2004 / Published online: 1 March 2005
© Springer-Verlag 2005

Abstract HAART-induced immune restoration is beneficial for patients with AIDS-related progressive multifocal leukoencephalopathy (PML). However, in rare instances, an immune-reconstitution inflammatory syndrome (IRIS) may cause paradoxical clinical deterioration. We report the neuropathological study of an AIDS

perivascular infiltration by T lymphocytes, and (2) acute perivenous leukoencephalitis devoid of JC virus. Most lymphocytes were CD8⁺ lymphocytes; CD4⁺ lymphocytes were virtually absent. Two pathological reactions were associated with the paradoxical clinical deterioration related to dysregulation of the immune

Acknowledgements

- I would like to thank:
- Professor Sebastian Lucas
- Professor Rob Miller
- Dr Fiona Burns
- Dr Ian Williams
- Sara Croxford